让人人都能从头设计蛋白！AlphaFold2幕后功臣创业，推出AI新模型，无需代码，一键快速设计蛋白

Core Viewpoint - Latent Labs has developed a groundbreaking generative AI model, Latent-X, which enables the design of functional protein binders with atomic-level precision, significantly improving the drug discovery process [6][7][26]. Group 1: Company Background - Simon Kohl, a former researcher at DeepMind, founded Latent Labs after leaving the company in late 2022, focusing on advanced protein design models to aid biopharmaceutical companies [2]. - Latent Labs secured $50 million in funding in February 2025 to further its mission in drug development [2]. Group 2: Technology and Innovation - Latent-X can design functional protein binders, including macrocyclic peptides and small protein binders, with unprecedented efficiency and accuracy [6][7]. - The model generates reliable protein binders by solving geometric challenges at the atomic level, producing high-affinity and specificity binders [7][20]. - Latent-X demonstrated a significant improvement in efficiency, requiring only 30-100 candidates per target to achieve results that typically need millions of candidates [7][18]. Group 3: Performance Validation - The research team tested Latent-X on seven benchmark target proteins related to viral infections, tumor regulation, and neurodegeneration [11][12]. - Latent-X achieved a hit rate of 91%-100% for macrocyclic peptides and 10%-64% for small protein binders across the target proteins [18]. - The best-designed macrocyclic peptides reached micromolar affinity, while small protein binders achieved picomolar affinity, surpassing other design models [19]. Group 4: Features and Usability - Latent-X allows users to generate both protein sequences and structures simultaneously, outperforming previous methods that generated them sequentially [23]. - The platform is user-friendly, requiring no coding skills, and provides a complete workflow for laboratory validation [21][29]. - Latent-X is scalable and has successfully generated various therapeutic binders, with plans for further expansion [22]. Group 5: Competitive Advantage - Latent-X excels in generating binders for previously unseen targets, achieving higher simulation hit rates with fewer samples compared to other models [24][28]. - The model adheres to atomic-level biochemical rules, creating structures that are chemically viable and suitable for drug development [28].